RANOLAZINE INTAS 500 mg PROLONGED-RELEASE TABLETS
How to use RANOLAZINE INTAS 500 mg PROLONGED-RELEASE TABLETS
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Ranolazine Intas 375 mg prolonged-release tablets EFG
Ranolazine Intas 500 mg prolonged-release tablets EFG
Ranolazine Intas 750 mg prolonged-release tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is Ranolazine Intas and what is it used for
- What you need to know before you take Ranolazine Intas
- How to take Ranolazine Intas
- Possible side effects
- Storage of Ranolazine Intas
- Contents of the pack and other information
1. What is Ranolazine Intas and what is it used for
Ranolazine Intas is a medicine that is used in combination with other medicines for the treatment of angina pectoris, which is a disease that causes chest pain or discomfort that can be felt in any part of the upper half of the body between the neck and the upper part of the abdomen, often after physical exercise or a particularly intense activity.
You should consult a doctor if it worsens or does not improve.
2. What you need to know before you take Ranolazine Intas
Do not take Ranolazine Intas
- If you are allergic to ranolazine or any of the other ingredients of this medicine included in section 6 of this leaflet.
- If you have severe kidney problems.
- If you have moderate or severe liver problems.
- If you are taking certain medicines for bacterial infections (clarithromycin, telithromycin), fungal infections (itraconazole, ketoconazole, voriconazole, posaconazole), HIV infection (AIDS) (protease inhibitors), depression (nefazodone) or heart rhythm disorders (e.g. quinidine, dofetilide or sotalol).
Warnings and precautions
Consult your doctor before taking Ranolazine Intas:
- If you have mild or moderate kidney problems.
- If you have mild liver problems.
- If you have ever had an electrocardiogram (ECG) abnormality
- If you are an elderly person.
- If you are a person of low weight (60 kg or less).
- If you have heart failure.
If you are in any of these situations, your doctor may decide to give you a lower dose of the medicine or take other precautions.
Using Ranolazine Intas with other medicines
Do not use any of the following medicines if you are taking Ranolazine Intas:
- Certain medicines for the treatment of bacterial infections (clarithromycin, telithromycin), fungal infections (itraconazole, ketoconazole, voriconazole, posaconazole), HIV infection (AIDS) (protease inhibitors), depression (nefazodone) or heart rhythm disorders (e.g. quinidine, dofetilide or sotalol).
Tell your doctor or pharmacist before taking Ranolazine Intas if you are using:
- Certain medicines for treating a bacterial infection (erythromycin) or a fungal infection (fluconazole), a medicine used to prevent organ rejection after a transplant (cyclosporine), or if you are taking heart pills such as diltiazem or verapamil. These medicines may cause a greater number of side effects, such as dizziness, nausea or vomiting, which are possible side effects of treatment with Ranolazine Intas (see section 4). If you are taking these medicines, your doctor may decide to give you a lower dose of Ranolazine Intas.
- Medicines for the treatment of epilepsy or other neurological disorders (e.g. phenytoin, carbamazepine or phenobarbital); if you are taking rifampicin to treat an infection (e.g. tuberculosis); or if you are taking a herbal medicine called St. John's Wort, you should inform your doctor because these medicines may make Ranolazine Intas less effective.
- Heart medicines that contain digoxin or metoprolol, as your doctor may decide to change the dose while you are taking Ranolazine Intas.
- Certain medicines for treating allergies (e.g. terfenadine, astemizole, mizolastine), heart rhythm disorders (e.g. disopyramide, procainamide) and medicines for treating depression (e.g. imipramine, doxepin, amitriptyline), as these medicines may alter your electrocardiogram (ECG).
- Certain medicines for treating depression (bupropion), psychosis, HIV infection (efavirenz) or cancer (cyclophosphamide).
- Certain medicines for treating high cholesterol levels in the blood (e.g. simvastatin, lovastatin, atorvastatin). These medicines may cause muscle pain and damage. Your doctor may decide to change the dose of this medicine while you are taking Ranolazine Intas.
- Certain medicines used to prevent organ rejection after a transplant (e.g. tacrolimus, cyclosporine, sirolimus, everolimus), so your doctor may decide to change the dose of this medicine while you are taking Ranolazine Intas.
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.
Using Ranolazine Intas with food and drinks
Ranolazine Intas can be taken with or without food. While you are being treated with Ranolazine Intas, you should not drink grapefruit juice.
Pregnancy
Do not take Ranolazine Intas if you are pregnant unless your doctor has told you that you can.
Breast-feeding
Do not take Ranolazine Intas if you are breast-feeding. Consult your doctor if you are breast-feeding.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and using machines
No studies on the effects of Ranolazine Intas on the ability to drive and use machines have been performed. Ask your doctor if you can drive or use machines.
Ranolazine Intas may cause side effects such as dizziness (frequent), blurred vision (uncommon), confusion (uncommon), hallucinations (uncommon), double vision (uncommon), coordination problems (rare), which may affect your ability to drive or use machines. If you notice any of these symptoms, do not drive or use machines until they have passed.
Ranolazine Intas 500 and 750 mg prolonged-release tablets contain lactose monohydrate. If your doctor has told you that you have an intolerance to some sugars, consult with them before taking this medicine.
This medicine contains less than 1 mmol of sodium (23 mg) per prolonged-release tablet, which is essentially "sodium-free".
3. How to take Ranolazine Intas
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Swallow the tablets whole with water. Do not chew, suck or crush the tablets or divide them in half, as this may affect the way the medicine is released in your body.
The initial dose for adults is one 375 mg tablet twice a day. After a period of time between 2 and 4 weeks, your doctor may increase the dose to achieve the desired effect. The maximum dose of Ranolazine Intas is 750 mg twice a day.
It is important that you inform your doctor if you experience side effects such as dizziness, nausea or vomiting. Your doctor may reduce the dose or, if that is not enough, tell you to stop taking the treatment with Ranolazine Intas.
Use in children and adolescents
Children and adolescents under 18 years of age should not take Ranolazine Intas.
If you take more Ranolazine Intas than you should
Go to your doctor, pharmacist or the nearest hospital emergency department immediately if you take more tablets than you should, and take this medicine with you.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount ingested.
If you forget to take Ranolazine Intas
If you forget to take a dose, take it as soon as you remember unless it is almost time for your next dose (less than 6 hours). Do not take a double dose to make up for forgotten doses.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You should stop taking Ranolazine Intas and consult your doctor immediately if you experience the following symptoms of angioedema, which is a rare but serious disorder:
- swelling of the face, tongue or throat
- difficulty swallowing
- hives or difficulty breathing
Tell your doctor if you experience frequent side effects such as dizziness, nausea or vomiting. Your doctor may reduce the dose or tell you to stop taking Ranolazine Intas.
The following are other side effects that you may experience:
Frequent side effects (occurring in between 1 and 10 in every 100 users):
Constipation
Dizziness
Headache
Nausea, vomiting
Weakness (asthenia)
Uncommon side effects (occurring in between 1 and 10 in every 1,000 users):
Altered sensitivity
Anxiety, difficulty sleeping, confusion, hallucinations
Blurred vision, vision disorders
Sensory disturbances (touch or taste), tremors, fatigue or weakness, somnolence or lethargy, weakness or fainting, dizziness when standing up
Dark urine, blood in the urine, difficulty urinating
Dehydration
Breathing difficulties, cough, nosebleeds
Double vision
Excessive sweating, itching
Feeling of swelling or bloating
Hot flashes, low blood pressure
Increased levels of a substance called creatinine, urea in the blood, platelet or white blood cell counts in the blood, altered electrocardiogram (ECG)
Swollen joints, pain in the limbs
Loss of appetite and/or weight loss
Muscle cramps, muscle weakness
Ringing in the ears and/or sensation of spinning
Stomach pain or discomfort, indigestion, dry mouth, or gas
Rare side effects (occurring in between 1 and 10 in every 10,000 users):
Urinary retention
Abnormal liver laboratory values
Acute kidney failure
Disturbances in the sense of smell, numbness of the mouth or lips, hearing loss
Cold sweats, rash
Coordination problems
Low blood pressure when standing up
Decreased level of consciousness or loss of consciousness
Disorientation
Cold sensation in hands and feet
Hives, allergic skin reactions
Impotence
Inability to walk due to balance problems
Pancreatitis or intestinal inflammation
Memory loss
Throat tightness
Low sodium levels in the blood (hyponatremia) that can cause fatigue and confusion, muscle contractions, cramps, and coma.
Side effects with unknown frequency (cannot be estimated from the available data):
Myoclonus
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Ranolazine Intas
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
6. Contents of the pack and other information
Composition of Ranolazine Intas
The active substance of Ranolazine Intas is ranolazine. Each tablet contains 375 mg, 500 mg or 750 mg of ranolazine.
The other ingredients are: magnesium stearate, microcrystalline cellulose, sodium hydroxide, titanium dioxide (E-171), [copolymer dispersion of methacrylic acid and ethyl acrylate (1:1) at 30%], hypromellose E5 (E-464).
Depending on the concentration of the tablet, the coating contains, in addition:
375 mg tablet: macrogol (E-1521), indigo carmine (E-132), polysorbate 80 (E-433).
500 mg tablet: lactose monohydrate, polyethylene glycol (E-1521), triacetin, yellow iron oxide (E172), red iron oxide (E172).
750 mg tablet: lactose monohydrate, triacetin, brilliant blue FCF (E133), tartrazine (E102).
Appearance of Ranolazine Intas and contents of the pack
Ranolazine Intas prolonged-release tablets are oval in shape.
The 375 mg tablets are pale blue in color and have "HI3" engraved on one side.
The 500 mg tablets are light orange in color and have "HI1" engraved on one side.
The 750 mg tablets are pale green in color and have "HI4" engraved on one side.
Ranolazine Intas is available in boxes with 30, 60 or 100 tablets in blisters.
Not all pack sizes may be marketed.
Marketing Authorisation Holder
Intas Third Party Sales 2005, S.L.,
World Trade Center, Moll Barcelona s/n, Edifici Est, 6ta. Planta
08039, Barcelona
Spain
Manufacturer
Laboratori Fundació Dau
C/ C, 12-14 Pol. Ind. Zona Franca
08040, Barcelona
Spain
or
Pharmadox Healthcare Limited
KW20A Kordin Industrial Park
3000, Paola
Malta
Date of last revision of this leaflet: December 2024
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
- Country of registration
- Active substance
- Prescription requiredYes
- Manufacturer
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to RANOLAZINE INTAS 500 mg PROLONGED-RELEASE TABLETSDosage form: MODIFIED-RELEASE TABLET, 375 mgActive substance: ranolazineManufacturer: Pharmathen S.A.Prescription requiredDosage form: MODIFIED-RELEASE TABLET, 500 mgActive substance: ranolazineManufacturer: Pharmathen S.A.Prescription requiredDosage form: MODIFIED-RELEASE TABLET, 750 mgActive substance: ranolazineManufacturer: Pharmathen S.A.Prescription required
Online doctors for RANOLAZINE INTAS 500 mg PROLONGED-RELEASE TABLETS
Discuss questions about RANOLAZINE INTAS 500 mg PROLONGED-RELEASE TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Frequently Asked Questions